- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02374684
Tolerability, Safety and Pharmacokinetic Study Of Methosulide in Healthy Adult Subjects
A Within-group Randomized, Double-Blind, Placebo-Controlled, Single/ Multiple Dose Study to Assess the Safety , Tolerability, Pharmacokinetics and Food Effect of Methosulide After Oral Administration In Healthy Adult Subjects.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
- Dose-escalation study of single oral administration of Methosulide in healthy adults to assess the safety and tolerability.
- Multiple-dose study of Methosulide in healthy adults to assess the safety and tolerability.
- Dose-escalation study of single oral administration of Methosulide in healthy adults to evaluate the pharmacokinetic characteristics
- Multiple-dose study of Methosulide in healthy adults to evaluate the pharmacokinetics characteristics
- Single dose,and cross-over study of Methosulide in healthy adults to evaluate the pharmacokinetic characteristics and effect of food.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
-
Wuhan,Hubei, China
- Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Male or female, between 18 and 45 years of age, Body Mass Index (BMI) between 19~25 kg/m2, Weight > or = 50kg
- In good health as judged by the investigator
- Without history of medication within 2 weeks before the test
- Non-allergic constitution, without known drug allergy
- Without history of major organ diseases
- Without other factors affecting drug metabolism, such as smoking (within 2 weeks), drinking (within 2 weeks), or drug abuse history
- Signed informed consent form and Fully understood the contents, process and possible adverse reactions of the test
Exclusion Criteria:
- History of kinds of food or drug allergy, or suffering from allergic diseases or allergic constitution
- Presence (in screening stage) or history of the acute/chronic organic diseases or clinical manifestations: blood system, renal disease, endocrine system, respiratory system, digestive system, cardiovascular system, nervous system, mental disease, allergic diseases (including drug allergy, but not including non-treatment, asymptomatic, seasonal allergy during the period of oral administration)
- History of abuse of Smoking, alcohol, or other drugs
- Severe hemorrhage factors to affect the venous blood collection
- Severe blood loss or blood donation within 3 months before the test
- Participation in other drug trials within 3 months before the test
- Usage of drugs known to have damage to the main organs within 3 months before the test
- Without good compliance, or unable to match with the test
- with a clinically significant abnormality in routine serological detection: including Hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV) infected
- For childbearing-aged women only, usage of any hormonal contraceptive methods within 3 months before the drug administration; or unable or unwilling to use non-hormonal contraceptive methods to contraception from the day of dosing until 14 days after dosing
- Be otherwise unsuitable for the study, in the opinion of the Investigator.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Placebo-Komparator: Placebo
Placebo, orale Verabreichung
|
Placebo passend zu Versuchsgruppen
|
Experimental: Methosulide
Methosulide, oral administration
|
Tolerability Study: Period I:Single oral administration,dose-escalation of Methosulide(six dose groups:25mg-250mg) Period II:Repeated oral administration of Methosulide(group 1:MTD(maximum tolerated dose)/250mg ,group 2:depending on the adverse drug reaction,150mg/250mg) Pharmacokinetic Study: Period I:Single oral administration,dose-escalation of Methosulide(three dose groups:50mg,100mg,200mg/250mg) Period II:Repeated oral administration of Methosulide(group 1:MTD(maximum tolerated dose)/250mg ,group 2:depending on the adverse drug reaction,150mg/250mg) Food Effect on the Pharmacokinetics: single dose(100mg),two status(Feeding and fasting), washout period(7 days)
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Safety and tolerability of single and repeated oral administration of Methosulide as measured by the frequency of drug-related clinical adverse events in healthy adults.
Zeitfenster: Period I: single dose,Baseline - 7 Days;Period II: repeated dose,Baseline - 14 Days
|
Adverse events, vital signs, electrocardiograms, physical exams, and clinical laboratory assessments will be assessed prior to, during, and after treatment
|
Period I: single dose,Baseline - 7 Days;Period II: repeated dose,Baseline - 14 Days
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Cmax of single oral administration of Methosulide and effect of food in healthy adults.
Zeitfenster: Baseline - 7 Days
|
Baseline - 7 Days
|
Tmax of single oral administration of Methosulide and effect of food in healthy adults.
Zeitfenster: Baseline - 7 Days
|
Baseline - 7 Days
|
area under curve(AUC) of single oral administration of Methosulide and effect of food in healthy adults.
Zeitfenster: Baseline - 7 Days
|
Baseline - 7 Days
|
t1/2α of single oral administration of Methosulide and effect of food in healthy adults.
Zeitfenster: Baseline - 7 Days
|
Baseline - 7 Days
|
t1/2β of single oral administration of Methosulide and effect of food in healthy adults.
Zeitfenster: Baseline - 7 Days
|
Baseline - 7 Days
|
Vd of single oral administration of Methosulide and effect of food in healthy adults.
Zeitfenster: Baseline - 7 Days
|
Baseline - 7 Days
|
Cls of single oral administration of Methosulide and effect of food in healthy adults.
Zeitfenster: Baseline - 7 Days
|
Baseline - 7 Days
|
Css of repeated oral administration of Methosulide in healthy adults.
Zeitfenster: Baseline - 14 Days
|
Baseline - 14 Days
|
Cmax of repeated oral administration of Methosulide in healthy adults.
Zeitfenster: Baseline - 14 Days
|
Baseline - 14 Days
|
Tmax of repeated oral administration of Methosulide in healthy adults.
Zeitfenster: Baseline - 14 Days
|
Baseline - 14 Days
|
area under curve(AUC) of repeated oral administration of Methosulide in healthy adults.
Zeitfenster: Baseline - 14 Days
|
Baseline - 14 Days
|
t1/2α of repeated oral administration of Methosulide in healthy adults.
Zeitfenster: Baseline - 14 Days
|
Baseline - 14 Days
|
t1/2β of repeated oral administration of Methosulide in healthy adults.
Zeitfenster: Baseline - 14 Days
|
Baseline - 14 Days
|
Vd of repeated oral administration of Methosulide in healthy adults.
Zeitfenster: Baseline - 14 Days
|
Baseline - 14 Days
|
Cls of repeated oral administration of Methosulide in healthy adults.
Zeitfenster: Baseline - 14 Days
|
Baseline - 14 Days
|
Mitarbeiter und Ermittler
Mitarbeiter
Ermittler
- Hauptermittler: ZHENG Heng, Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Andere Studien-ID-Nummern
- HubeiBMITI- CM2010-01-I
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Placebo
-
SamA Pharmaceutical Co., LtdUnbekanntAkute Bronchitis | Akute Infektion der oberen AtemwegeKorea, Republik von
-
National Institute on Drug Abuse (NIDA)AbgeschlossenCannabiskonsumVereinigte Staaten
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyAbgeschlossenMännliche Probanden mit Typ-II-Diabetes (T2DM)Deutschland
-
Instituto de Investigación Hospital Universitario...Creaciones Aromáticas Industriales, S.A. (CARINSA)Abgeschlossen
-
Soroka University Medical CenterAbgeschlossen
-
Regado Biosciences, Inc.AbgeschlossenGesunder FreiwilligerVereinigte Staaten
-
Texas A&M UniversityNutraboltAbgeschlossenGlucose and Insulin Response
-
Longeveron Inc.BeendetHypoplastisches LinksherzsyndromVereinigte Staaten
-
Heptares Therapeutics LimitedAbgeschlossenPharmakokinetik | SicherheitsproblemeVereinigtes Königreich